Best Stocks Under $2 | Low-Priced Stocks for Two Dollars or Less

1. Ur Energy NYSEAMERICAN:URG

$1.08 -0.03 (-2.70%)

Closing price 04:10 PM Eastern

Extended Trading

$1.10 +0.01 (+1.39%)

As of 07:59 PM Eastern

Ur-Energy Inc engages in the acquisition, exploration, development, and operation of uranium mineral properties. The company holds interests in 12 projects located in the United States. More about Ur Energy

Market Capitalization: $441.10 million
Consensus Rating: Buy
Consensus Price Target: $2.28 (+111.1% Upside)
Volume: 11.68 million shares
Average Volume: 6.17 million shares
Today's Range: $1.08
▼
$1.14

2. Nouveau Monde Graphite NYSE:NMG

$1.20 +0.03 (+2.14%)

Closing price 03:59 PM Eastern

Extended Trading

$1.23 +0.03 (+2.76%)

As of 07:56 PM Eastern

Nouveau Monde Graphite Inc engages in the acquisition, exploration, development, and evaluation of mineral properties in Quebec, Canada. More about Nouveau Monde Graphite

Market Capitalization: $385.11 million
Consensus Rating: Buy
Consensus Price Target: $4.67 (+290.5% Upside)
Volume: 583,989 shares
Average Volume: 366,323 shares
Today's Range: $1.18
▼
$1.22

3. iBio NASDAQ:IBIO

$1.18 +0.01 (+0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 +0.03 (+2.46%)

As of 07:57 PM Eastern

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. More about iBio

Market Capitalization: $75.24 million
Consensus Rating: Buy
Consensus Price Target: $5.29 (+347.9% Upside)
Volume: 227,917 shares
Average Volume: 502,541 shares
Today's Range: $1.17
▼
$1.22

4. Galiano Gold NYSEAMERICAN:GAU

$1.94 -0.04 (-2.02%)

Closing price 04:10 PM Eastern

Extended Trading

$1.94 0.00 (-0.26%)

As of 07:30 PM Eastern

Galiano Gold Inc engages in the exploration and evaluation of gold properties in Canada. Its flagship asset is the Asanko Gold Mine that covers an area of approximately 21,000 hectares located in Ghana, West Africa. More about Galiano Gold

Market Capitalization: $517.83 million
P/E Ratio: 7.46
Consensus Rating: Buy
Consensus Price Target: $4.25 (+119.1% Upside)
Volume: 1.65 million shares
Average Volume: 2.34 million shares

5. Stereotaxis NYSEAMERICAN:STXS

$1.23 -0.02 (-1.60%)

Closing price 04:10 PM Eastern

Extended Trading

$1.27 +0.04 (+3.25%)

As of 07:30 PM Eastern

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. More about Stereotaxis

Market Capitalization: $125.25 million
Consensus Rating: Buy
Consensus Price Target: $3.50 (+184.6% Upside)
Volume: 335,829 shares
Average Volume: 499,430 shares
Today's Range: $1.23
▼
$1.27

6. Palisade Bio NASDAQ:PALI

$1.35 -0.10 (-6.90%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 +0.01 (+0.67%)

As of 07:56 PM Eastern

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. More about Palisade Bio

Market Capitalization: $252.69 million
Consensus Rating: Buy
Consensus Price Target: $9.83 (+628.4% Upside)
Volume: 4.77 million shares
Average Volume: 3.66 million shares
Today's Range: $1.32
▼
$1.46

7. Equillium NASDAQ:EQ

$1.62 +0.01 (+0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.59 -0.03 (-2.03%)

As of 07:56 PM Eastern

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More about Equillium

Market Capitalization: $102.72 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.57 (+365.9% Upside)
Volume: 3.10 million shares
Average Volume: 538,107 shares
Today's Range: $1.58
▼
$1.66

8. Cabaletta Bio NASDAQ:CABA

$1.92 -0.06 (-2.93%)

Closing price 03:59 PM Eastern

Extended Trading

$1.95 +0.03 (+1.46%)

As of 07:58 PM Eastern

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More about Cabaletta Bio

Market Capitalization: $335.70 million
Consensus Rating: Moderate Buy
Consensus Price Target: $15.33 (+697.8% Upside)
Volume: 8.05 million shares
Average Volume: 5.90 million shares
Today's Range: $1.90
▼
$2.01

9. Autolus Therapeutics NASDAQ:AUTL

$1.94 +0.08 (+4.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.95 +0.01 (+0.41%)

As of 07:55 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. More about Autolus Therapeutics

Market Capitalization: $495.06 million
Consensus Rating: Moderate Buy
Consensus Price Target: $10.00 (+415.5% Upside)
Volume: 1.16 million shares
Average Volume: 1.56 million shares
Today's Range: $1.87
▼
$1.99

10. Canaan NASDAQ:CAN

$0.34 -0.03 (-7.38%)

Closing price 04:00 PM Eastern

Extended Trading

$0.35 +0.00 (+0.58%)

As of 07:44 PM Eastern

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization: $266.79 million
Consensus Rating: Moderate Buy
Consensus Price Target: $1.92 (+455.6% Upside)
Volume: 12.64 million shares
Average Volume: 14.55 million shares
Today's Range: $0.34
▼
$0.40

11. Tenaya Therapeutics NASDAQ:TNYA

$0.60 +0.01 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.00 (+0.56%)

As of 07:53 PM Eastern

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization: $132.99 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.00 (+562.7% Upside)
Volume: 1.81 million shares
Average Volume: 2.40 million shares
Today's Range: $0.60
▼
$0.62

12. NervGen Pharma NASDAQ:NGEN

$1.91 -0.01 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 0.00 (-0.26%)

As of 07:30 PM Eastern

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. More about NervGen Pharma

Market Capitalization: $154.81 million
Consensus Rating: Moderate Buy
Consensus Price Target: $14.00 (+633.0% Upside)
Volume: 548,444 shares
Average Volume: 472,670 shares
Today's Range: $1.90
▼
$1.98

13. Rani Therapeutics NASDAQ:RANI

$0.79 -0.01 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 +0.02 (+3.16%)

As of 07:30 PM Eastern

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. More about Rani Therapeutics

Market Capitalization: $111.56 million
Consensus Rating: Moderate Buy
Consensus Price Target: $8.75 (+1,006.2% Upside)
Volume: 468,153 shares
Average Volume: 507,704 shares
Today's Range: $0.78
▼
$0.82

14. AEON Biopharma NASDAQ:AEON

$0.30 +0.04 (+15.83%)

Closing price 04:00 PM Eastern

Extended Trading

$0.29 -0.01 (-2.67%)

As of 07:59 PM Eastern

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. More about AEON Biopharma

Market Capitalization: $14.97 million
P/E Ratio: 1.67
Consensus Rating: Moderate Buy
Consensus Price Target: $1.33 (+344.4% Upside)
Volume: 115.85 million shares
Average Volume: 2.92 million shares

15. SKYX Platforms NASDAQ:SKYX

$1.15 +0.02 (+1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.03 (+2.17%)

As of 07:51 PM Eastern

SKYX Platforms Corp. provides a series of safe-smart platform technologies. The company's first and second-generation technologies enable light fixtures, ceiling fans, and other electrically wired products to be installed and plugged into a ceiling's electrical outlet box. More about SKYX Platforms

Market Capitalization: $153.04 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.67 (+305.8% Upside)
Volume: 568,668 shares
Average Volume: 816,708 shares
Today's Range: $1.15
▼
$1.20

16. Standard Lithium NYSEAMERICAN:SLI

$1.83 +0.03 (+1.67%)

As of 04:10 PM Eastern

Standard Lithium Ltd. explores for, develops, and processes lithium brine properties in the United States. Its flagship project is the Lanxess project with area of approximately 150,000 acres located in southern Arkansas. More about Standard Lithium

Market Capitalization: $444.21 million
Consensus Rating: Moderate Buy
Consensus Price Target: $5.16 (+182.1% Upside)
Volume: 2.37 million shares
Average Volume: 1.77 million shares
Today's Range: $1.81
▼
$1.92

17. PMV Pharmaceuticals NASDAQ:PMVP

$1.67 +0.24 (+16.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.66 -0.01 (-0.54%)

As of 07:59 PM Eastern

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. More about PMV Pharmaceuticals

Market Capitalization: $76.44 million
Consensus Rating: Moderate Buy
Consensus Price Target: $4.33 (+159.5% Upside)
Volume: 3.12 million shares
Average Volume: 596,578 shares
Today's Range: $1.44
▼
$1.73

18. Cellectar Biosciences NASDAQ:CLRB

$1.84 +0.02 (+1.10%)

Closing price 04:00 PM Eastern

Extended Trading

$1.84 -0.01 (-0.27%)

As of 07:30 PM Eastern

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. More about Cellectar Biosciences

Market Capitalization: $17.20 million
Consensus Rating: Moderate Buy
Consensus Price Target: $11.00 (+497.8% Upside)
Volume: 74,863 shares
Average Volume: 60,363 shares
Today's Range: $1.82
▼
$1.92

19. Caribou Biosciences NASDAQ:CRBU

$1.26 +0.03 (+2.02%)

Closing price 03:59 PM Eastern

Extended Trading

$1.26 0.00 (0.00%)

As of 07:49 PM Eastern

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. More about Caribou Biosciences

Market Capitalization: $132.94 million
Consensus Rating: Moderate Buy
Consensus Price Target: $7.75 (+512.6% Upside)
Volume: 844,800 shares
Average Volume: 1.15 million shares
Today's Range: $1.25
▼
$1.29

20. Allogene Therapeutics NASDAQ:ALLO

$1.60 -0.02 (-1.23%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 +0.00 (+0.31%)

As of 07:53 PM Eastern

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. More about Allogene Therapeutics

Market Capitalization: $559.70 million
Consensus Rating: Moderate Buy
Consensus Price Target: $8.30 (+418.8% Upside)
Volume: 8.13 million shares
Average Volume: 5.47 million shares
Today's Range: $1.58
▼
$1.66

21. Neumora Therapeutics NASDAQ:NMRA

$0.60 -0.08 (-12.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 +0.00 (+0.47%)

As of 07:17 PM Eastern

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. More about Neumora Therapeutics

Market Capitalization: $127.32 million
Consensus Rating: Moderate Buy
Consensus Price Target: $6.57 (+1,002.2% Upside)
Volume: 2.28 million shares
Average Volume: 1.64 million shares
Today's Range: $0.59
▼
$0.69

22. Tvardi Therapeutics NASDAQ:TVRD

$1.25 -0.03 (-2.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 +0.03 (+2.40%)

As of 07:26 PM Eastern

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. More about Tvardi Therapeutics

Market Capitalization: $17.07 million
Consensus Rating: Moderate Buy
Consensus Price Target: $18.00 (+1,340.0% Upside)
Volume: 232,643 shares
Average Volume: 203,374 shares
Today's Range: $1.20
▼
$1.32

23. Compass Therapeutics NASDAQ:CMPX

$1.04 -0.06 (-5.45%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 +0.00 (+0.38%)

As of 07:55 PM Eastern

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. More about Compass Therapeutics

Market Capitalization: $198.10 million
Consensus Rating: Moderate Buy
Consensus Price Target: $10.21 (+882.1% Upside)
Volume: 5.65 million shares
Average Volume: 4.55 million shares
Today's Range: $1.02
▼
$1.10

24. Connect Biopharma NASDAQ:CNTB

$1.10 +0.11 (+10.89%)

Closing price 04:00 PM Eastern

Extended Trading

$1.10 0.00 (-0.36%)

As of 07:59 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. More about Connect Biopharma

Market Capitalization: $62.47 million
Consensus Rating: Moderate Buy
Consensus Price Target: $6.14 (+458.4% Upside)
Volume: 164.84 million shares
Average Volume: 2.16 million shares
Today's Range: $1.07
▼
$1.89

25. Inovio Pharmaceuticals NASDAQ:INO

$1.22 +0.11 (+9.91%)

Closing price 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.82%)

As of 07:59 PM Eastern

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. More about Inovio Pharmaceuticals

Market Capitalization: $114.77 million
Consensus Rating: Moderate Buy
Consensus Price Target: $3.17 (+159.6% Upside)
Volume: 2.66 million shares
Average Volume: 2.79 million shares
Today's Range: $1.13
▼
$1.24

Best Stocks Under $2 Right Now

1. Ur Energy NYSEAMERICAN:URG

2. Nouveau Monde Graphite NYSE:NMG

3. iBio NASDAQ:IBIO

4. Galiano Gold NYSEAMERICAN:GAU

5. Stereotaxis NYSEAMERICAN:STXS

6. Palisade Bio NASDAQ:PALI

7. Equillium NASDAQ:EQ

8. Cabaletta Bio NASDAQ:CABA

9. Autolus Therapeutics NASDAQ:AUTL

10. Canaan NASDAQ:CAN

11. Tenaya Therapeutics NASDAQ:TNYA

12. NervGen Pharma NASDAQ:NGEN

13. Rani Therapeutics NASDAQ:RANI

14. AEON Biopharma NASDAQ:AEON

15. SKYX Platforms NASDAQ:SKYX

16. Standard Lithium NYSEAMERICAN:SLI

17. PMV Pharmaceuticals NASDAQ:PMVP

18. Cellectar Biosciences NASDAQ:CLRB

19. Caribou Biosciences NASDAQ:CRBU

20. Allogene Therapeutics NASDAQ:ALLO

21. Neumora Therapeutics NASDAQ:NMRA

22. Tvardi Therapeutics NASDAQ:TVRD

23. Compass Therapeutics NASDAQ:CMPX

24. Connect Biopharma NASDAQ:CNTB

25. Inovio Pharmaceuticals NASDAQ:INO

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Best Stocks Under $2 Right Now

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools